Showing results (131-140 of 255) with videos related to

Sort By:
Pageof 26
Cancer Research|February 28, 2001
Loss of Fhit expression is a predictor of poor outcome in tongue cancerJ I Lee, J C Soria, K Hassan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 1999
Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patientsJ C Soria, L R Gauthier, E Raymond, et al.
The Oncologist|February 22, 2001
Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancerT Le Chevalier, D Brisgand, J C Soria, et al.
Revue Des Maladies Respiratoires|February 22, 2008
[The role of radiotherapy in the management of patients with small cell lung cancer]C Daveau, C Le Péchoux, B Besse, et al.
Circulation|November 1, 1995
Clinical study of the effects of latissimus dorsi muscle flap stimulation after cardiomyoplastyA A Hagège, M Desnos, F Fernandez, et al.
American Heart Journal|May 1, 1996
Rotational atherectomy with adjunctive balloon angioplasty versus conventional percutaneous transluminal coronary angioplasty in type B2 lesions: results of a randomized studyY Guérin, C Spaulding, M Desnos, et al.
Revue De Pneumologie Clinique|October 12, 2010
[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)]J Margery, F Rivière, D Planchard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2023
ESMO study on the availability and accessibility of biomolecular technologies in oncology in EuropeA Bayle, J Bonastre, D Chaltiel, et al.
Medical Oncology (Northwood, London, England)|April 1, 2003
Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcomaJ-P Spano, J-C Soria, M Kambouchner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2015
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phaseN Isambert, J-P Delord, J-C Soria, et al.
Pageof 26